Successful Guselkumab Treatment of a Refractory Psoriasis Patient with Graves' Disease: a Case Report

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2024 Apr 24

PMID 38656269

Authors

Xinyi Shao

Kun Huang

Aijun Chen

Chuan Liu

Jianxia Xiong

Yun Pan

Xiaoli Chen

Ping Wang

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a chronic inflammatory skin disease. It is associated with many autoimmune diseases such as rheumatoid arthritis, Crohn's disease and thyroid diseases. Graves' disease (GD) is a common organ-specific autoimmune disease characterized by diffuse goitre and thyrotoxicosis. Management of psoriasis patients with GD is challenging. This current report presents the case of a 34-year-old female patient with refractory psoriasis with GD who was hospitalized for drug eruption and then experienced new-onset erythema and scaling following treatment with adalimumab and secukinumab. Despite the sequential move to phototherapy, tofacitinib and ustekinumab, the erythema and scaling continued unabated and exacerbated. Finally, switching to guselkumab resulted in the psoriasis lesions significantly improving. These findings suggest that guselkumab might be an effective treatment option for refractory psoriasis combined with GD.

References

Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E . Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2020; 35(4):938-947. PMC: 7986088. DOI: 10.1111/jdv.17002. View

Griffiths C, Barker J . Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370(9583):263-271. DOI: 10.1016/S0140-6736(07)61128-3. View

Havmose M, Thomsen S . Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases. Int J Dermatol. 2017; 56(11):1087-1102. DOI: 10.1111/ijd.13691. View

Hawkes J, Yan B, Chan T, Krueger J . Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol. 2018; 201(6):1605-1613. PMC: 6129988. DOI: 10.4049/jimmunol.1800013. View

Langley R, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren R . Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023; 188(2):198-207. DOI: 10.1093/bjd/ljac040. View

Blauvelt A, Papp K, Griffiths C, Randazzo B, Wasfi Y, Shen Y . Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active.... J Am Acad Dermatol. 2017; 76(3):405-417. DOI: 10.1016/j.jaad.2016.11.041. View

Parisi R, Symmons D, Griffiths C, Ashcroft D . Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2012; 133(2):377-85. DOI: 10.1038/jid.2012.339. View

Abbruzzese A, Venerito V, Lopalco G, Fornaro M, Giannotta M, Iannone F . Paradoxical Pustular Psoriasis in a Patient With Psoriatic Arthritis on Secukinumab Treatment. J Clin Rheumatol. 2019; 26(6):e208-e209. DOI: 10.1097/RHU.0000000000001076. View

Ghoreschi K, Balato A, Enerback C, Sabat R . Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021; 397(10275):754-766. DOI: 10.1016/S0140-6736(21)00184-7. View

10.

Yiu Z, Becher G, Kirby B, Laws P, Reynolds N, Smith C . Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis. JAMA Dermatol. 2022; 158(10):1131-1141. PMC: 9260644. DOI: 10.1001/jamadermatol.2022.2909. View

11.

Gagnier J, Kienle G, Altman D, Moher D, Sox H, Riley D . The CARE guidelines: consensus-based clinical case reporting guideline development. Headache. 2013; 53(10):1541-7. DOI: 10.1111/head.12246. View

12.

Gul U, Gonul M, Kaya I, Aslan E . Autoimmune thyroid disorders in patients with psoriasis. Eur J Dermatol. 2009; 19(3):221-3. DOI: 10.1684/ejd.2009.0632. View

13.

Eapi S, Chowdhury R, Lawal O, Mathur N, Malik B . Etiological Association Between Psoriasis and Thyroid Diseases. Cureus. 2021; 13(1):e12653. PMC: 7872875. DOI: 10.7759/cureus.12653. View

14.

Gooderham M, Papp K, Lynde C . Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018; 32(7):1111-1119. PMC: 6033004. DOI: 10.1111/jdv.14868. View

15.

Jia H, Tao F, Liu C, Guo T, Zhu W, Wang S . Both interleukin-23A polymorphism and serum interlukin-23 expression are associated with Graves' disease risk. Cell Immunol. 2015; 294(1):39-43. DOI: 10.1016/j.cellimm.2015.01.015. View

16.

Menter A, Strober B, Kaplan D, Kivelevitch D, Prater E, Stoff B . Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019; 80(4):1029-1072. DOI: 10.1016/j.jaad.2018.11.057. View

17.

Ren X, Chen H . Changes in Th9 and Th17 lymphocytes and functional cytokines and their relationship with thyroid-stimulating hormone receptor antibodies at different stages of graves' disease. Front Immunol. 2022; 13:919681. PMC: 9352852. DOI: 10.3389/fimmu.2022.919681. View

18.

Langley R, Tsai T, Flavin S, Song M, Randazzo B, Wasfi Y . Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2017; 178(1):114-123. DOI: 10.1111/bjd.15750. View

19.

Sigurgeirsson B, Browning J, Tyring S, Szepietowski J, Rivera-Diaz R, Effendy I . Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial. Dermatol Ther. 2021; 35(3):e15285. DOI: 10.1111/dth.15285. View

20.

Simsek T, Yildirim N, Efe B, Kebapci N . Rituximab Treatment in a Patient with Active Graves' Orbitopathy and Psoriasis. Turk J Ophthalmol. 2017; 47(1):42-46. PMC: 5282540. DOI: 10.4274/tjo.26780. View